Abstract
Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet function and possesses a strong vasodilator effect. Furthermore, prostacyclin is currently presented as the physiologic antagonist of thromboxane A2 (TXA2), which exhibits pro-aggregatory and vasoconstrictor properties. So, the balance between PGI2 and TXA2 production is crucial for the cardiovascular system. Indeed, an imbalance in the production or effect of these products is deleterious for the circulatory system and can lead to characterized vascular diseases such as hypertension, stroke, atherosclerosis or myocardial infarction. Although the biological effects of PGI2 are considered to be clinically useful, its use as therapeutic agent is largely limited by both its chemical and metabolic instability. Actually, several prostacyclin agonists have been synthesized and pharmacologically evaluated. Among these, some have been clinically evaluated as therapeutic agents in several vascular diseases. This review focuses on the latest chemical and pharmacological developments in the field of the prostacyclin agonists.
Keywords: thromboxane, prostacyclin modulators, prostacyclin, hypertension, stroke, atherosclerosis, myocardial infarction
Current Medicinal Chemistry
Title: New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators
Volume: 11 Issue: 10
Author(s): Xavier de Leval, Julien Hanson, Jean-Louis David, Bernard Masereel, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Keywords: thromboxane, prostacyclin modulators, prostacyclin, hypertension, stroke, atherosclerosis, myocardial infarction
Abstract: Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet function and possesses a strong vasodilator effect. Furthermore, prostacyclin is currently presented as the physiologic antagonist of thromboxane A2 (TXA2), which exhibits pro-aggregatory and vasoconstrictor properties. So, the balance between PGI2 and TXA2 production is crucial for the cardiovascular system. Indeed, an imbalance in the production or effect of these products is deleterious for the circulatory system and can lead to characterized vascular diseases such as hypertension, stroke, atherosclerosis or myocardial infarction. Although the biological effects of PGI2 are considered to be clinically useful, its use as therapeutic agent is largely limited by both its chemical and metabolic instability. Actually, several prostacyclin agonists have been synthesized and pharmacologically evaluated. Among these, some have been clinically evaluated as therapeutic agents in several vascular diseases. This review focuses on the latest chemical and pharmacological developments in the field of the prostacyclin agonists.
Export Options
About this article
Cite this article as:
Leval de Xavier, Hanson Julien, David Jean-Louis, Masereel Bernard, Pirotte Bernard and Dogne Jean-Michel, New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators, Current Medicinal Chemistry 2004; 11 (10) . https://dx.doi.org/10.2174/0929867043365279
DOI https://dx.doi.org/10.2174/0929867043365279 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ovulation, Implantation and Placentation in Females with Obesity and Metabolic Disorders: Life in the Balance
Endocrine, Metabolic & Immune Disorders - Drug Targets Peripheral Arterial Disease - The Forgotten Risk Factor
Vascular Disease Prevention (Discontinued) Multifunctional RNase MCPIP1 and its Role in Cardiovascular Diseases
Current Medicinal Chemistry Carotid Intima Media Thickness and Beyond
Current Drug Targets - Cardiovascular & Hematological Disorders Oxidative/Nitrosative Stress and Immuno-inflammatory Pathways in Depression: Treatment Implications
Current Pharmaceutical Design Recent Progress in Signal Transduction Research of the Angiotensin II Type-1 Receptor: Protein Kinases, Vascular Dysfunction and Structural Requirement
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Effect of Dietary Education on Cardiovascular Risk Factors in Rheumatoid Arthritis Patients
Current Rheumatology Reviews Experimental Benefits of Sex Hormones on Vascular Function and the Outcome of Hormone Therapy in Cardiovascular Disease
Current Cardiology Reviews Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets The Effects of Vitamin B in Depression
Current Medicinal Chemistry Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Classical to Current Approach for Treatment of Psoriasis: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of α7-Nicotinic Acetylcholine Receptor in Normal and Cancer Stem Cells
Current Drug Targets Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Diabetic Nephropathy: Causes and Managements
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Novel Methods of Insulin Replacement: The Artificial Pancreas and Encapsulated Islets
Reviews on Recent Clinical Trials Not a Painless Condition: Rheumatological and Musculoskeletal Symptoms in Type 2 Diabetes, and the Implications for Exercise Participation
Current Diabetes Reviews Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Studies on the Biotransformations and Biodistributions of Metal-Containing Drugs Using X-Ray Absorption Spectroscopy
Current Topics in Medicinal Chemistry